EP0946164A4 - Integrin antagonists - Google Patents
Integrin antagonistsInfo
- Publication number
- EP0946164A4 EP0946164A4 EP97913775A EP97913775A EP0946164A4 EP 0946164 A4 EP0946164 A4 EP 0946164A4 EP 97913775 A EP97913775 A EP 97913775A EP 97913775 A EP97913775 A EP 97913775A EP 0946164 A4 EP0946164 A4 EP 0946164A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- integrin antagonists
- integrin
- antagonists
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/73—Unsubstituted amino or imino radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/06—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D239/08—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms directly attached in position 2
- C07D239/12—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/06—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D239/08—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms directly attached in position 2
- C07D239/12—Nitrogen atoms not forming part of a nitro radical
- C07D239/14—Nitrogen atoms not forming part of a nitro radical with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to said nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2922396P | 1996-10-30 | 1996-10-30 | |
| US29223P | 1996-10-30 | ||
| GBGB9626308.2A GB9626308D0 (en) | 1996-12-18 | 1996-12-18 | av›3 antagonists |
| GB9626308 | 1996-12-18 | ||
| PCT/US1997/019349 WO1998018461A1 (en) | 1996-10-30 | 1997-10-27 | Integrin antagonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EP0946164A1 EP0946164A1 (en) | 1999-10-06 |
| EP0946164A4 true EP0946164A4 (en) | 2000-08-23 |
Family
ID=26310673
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP97913775A Withdrawn EP0946164A4 (en) | 1996-10-30 | 1997-10-27 | Integrin antagonists |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP0946164A4 (en) |
| JP (1) | JP2001504456A (en) |
| AU (1) | AU717283B2 (en) |
| WO (1) | WO1998018461A1 (en) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6017926A (en) * | 1997-12-17 | 2000-01-25 | Merck & Co., Inc. | Integrin receptor antagonists |
| US6048861A (en) | 1997-12-17 | 2000-04-11 | Merck & Co., Inc. | Integrin receptor antagonists |
| US6066648A (en) * | 1997-12-17 | 2000-05-23 | Merck & Co., Inc. | Integrin receptor antagonists |
| US6211191B1 (en) | 1997-12-17 | 2001-04-03 | Merck & Co., Inc. | Integrin receptor antagonists |
| NZ509797A (en) * | 1998-07-10 | 2003-11-28 | Univ Sydney | Prophylactic treatments of neovascularisation in macular degeneration using a steroid |
| AU747784B2 (en) * | 1998-07-29 | 2002-05-23 | Merck & Co., Inc. | Integrin receptor antagonists |
| EP1105389A4 (en) * | 1998-08-13 | 2001-10-17 | Merck & Co Inc | Integrin receptor antagonists |
| FR2786182B1 (en) * | 1998-11-24 | 2001-01-12 | Hoechst Marion Roussel Inc | NOVEL ACYLGUANIDINES DERIVATIVES, PROCESS FOR THEIR PREPARATION, THEIR USE AS MEDICAMENTS AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
| US6677360B2 (en) | 1998-12-16 | 2004-01-13 | Bayer Aktiengesellschaft | Biphenyl and biphenyl-analogous compounds as integrin antagonists |
| US6291503B1 (en) | 1999-01-15 | 2001-09-18 | Bayer Aktiengesellschaft | β-phenylalanine derivatives as integrin antagonists |
| CZ20013678A3 (en) * | 1999-04-13 | 2002-07-17 | Basf Aktiengesellschaft | Ligands of integrin receptor |
| DZ3263A1 (en) | 1999-06-02 | 2000-12-07 | Merck & Co Inc | ALPHA V INTEGRIN RECEPTOR ANTAGONISTS |
| WO2000075129A1 (en) * | 1999-06-07 | 2000-12-14 | Shire Biochem Inc. | Thiophene integrin inhibitors |
| EP1065208A1 (en) * | 1999-07-02 | 2001-01-03 | Aventis Pharma Deutschland GmbH | Substituted purine derivatives as inhibitors of cell adhesion |
| EP1065207A1 (en) * | 1999-07-02 | 2001-01-03 | Aventis Pharma Deutschland GmbH | Naphthyridine derivatives, processes for their preparation, their use, and pharmaceutical compositions comprising them |
| DE19939981A1 (en) * | 1999-08-24 | 2001-03-01 | Merck Patent Gmbh | New inhibitors of the integrin alphavß3 |
| US6514964B1 (en) | 1999-09-27 | 2003-02-04 | Amgen Inc. | Fused cycloheptane and fused azacycloheptane compounds and their methods of use |
| EP1229910A4 (en) * | 1999-10-04 | 2003-10-01 | Merck & Co Inc | Integrin receptor antagonists |
| DE10039998A1 (en) * | 2000-08-11 | 2002-02-21 | Basf Ag | New substituted diareno-azepine derivatives as integrin ligands |
| WO2001027082A1 (en) * | 1999-10-08 | 2001-04-19 | Meiji Seika Kaisha, Ltd. | 3-AMINOPIPERIDINE DERIVATIVES AS INTEGRIN αvβ3 ANTAGONISTS |
| US6849639B2 (en) | 1999-12-14 | 2005-02-01 | Amgen Inc. | Integrin inhibitors and their methods of use |
| EP1252162B1 (en) * | 2000-01-20 | 2012-07-25 | Merck Sharp & Dohme Corp. | Alpha v integrin receptor antagonists |
| US6545029B2 (en) | 2000-06-12 | 2003-04-08 | Bayer Aktiengesellschaft | Phenylserine derivatives as integrin antagonists |
| ES2376161T3 (en) * | 2001-01-29 | 2012-03-09 | Janssen Pharmaceuticals, Inc. | SUBSTITUTE INDOLES AND THEIR USE AS AN INTEGRINE ANTAGONISTS. |
| DK1371646T3 (en) | 2001-03-19 | 2010-07-05 | Dainippon Sumitomo Pharma Co | Aryl-substituted alicyclic compound and medical composition comprising the same |
| RU2316337C2 (en) | 2001-04-24 | 2008-02-10 | Мерк Патент Гмбх | Combined therapy by using antiangiogenic agents and tnf-alpha |
| GB0112834D0 (en) | 2001-05-25 | 2001-07-18 | Smithkline Beecham Plc | Medicaments |
| US7115596B2 (en) | 2002-12-20 | 2006-10-03 | Pharmacia Corporation | Thiazole compounds as integrin receptor antagonists derivatives |
| ES2521679T3 (en) | 2006-01-18 | 2014-11-13 | Merck Patent Gmbh | Specific therapy using integrin ligands for cancer treatment |
| MX2009007597A (en) | 2007-01-18 | 2009-07-22 | Merck Patent Gmbh | Specific therapy and medicament using integrin ligands for treating cancer. |
| EA201101651A1 (en) | 2009-05-25 | 2012-08-30 | Мерк Патент Гмбх | CONTINUOUS INTRODUCTION OF INTEGRINE LIGANDS FOR CANCER TREATMENT |
| PL3929196T3 (en) | 2013-09-24 | 2023-12-11 | Fujifilm Corporation | Pharmaceutical composition of a nitrogen-containing compound or salt thereof, or metal complex thereof |
| DK3054936T5 (en) | 2013-10-10 | 2024-03-18 | Eastern Virginia Medical School | 4-((2-HYDROXY-3-METHOXYBENZYL)AMINO) BENZENESULFONAMIDE DERIVATIVES AS 12-LIPOXYGENASE INHIBITORS |
| CN106572997A (en) | 2014-05-30 | 2017-04-19 | 辉瑞公司 | Carbonitrile derivatives as selective androgen receptor modulators |
| WO2023275715A1 (en) | 2021-06-30 | 2023-01-05 | Pfizer Inc. | Metabolites of selective androgen receptor modulators |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998025892A1 (en) * | 1996-12-09 | 1998-06-18 | Eli Lilly And Company | Integrin antagonists |
| WO1998044797A1 (en) * | 1997-04-07 | 1998-10-15 | Merck & Co., Inc. | A method of treating cancer |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5416099A (en) * | 1991-10-29 | 1995-05-16 | Merck & Co., Inc. | Fibrinogen receptor antagonists |
| EP0760658B1 (en) * | 1994-05-27 | 2002-11-13 | Merck & Co. Inc. | Compounds for inhibiting osteoclast-mediated bone resorption |
-
1997
- 1997-10-27 AU AU50884/98A patent/AU717283B2/en not_active Ceased
- 1997-10-27 EP EP97913775A patent/EP0946164A4/en not_active Withdrawn
- 1997-10-27 JP JP52063998A patent/JP2001504456A/en active Pending
- 1997-10-27 WO PCT/US1997/019349 patent/WO1998018461A1/en not_active Application Discontinuation
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998025892A1 (en) * | 1996-12-09 | 1998-06-18 | Eli Lilly And Company | Integrin antagonists |
| WO1998044797A1 (en) * | 1997-04-07 | 1998-10-15 | Merck & Co., Inc. | A method of treating cancer |
Non-Patent Citations (2)
| Title |
|---|
| EGBERTSON M S ET AL: "Nonpeptide GPIIB/IIIA inhibitors. 10. centrally constrained alpha-sulfonamides are potent inhibitors of platelet aggregation", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,GB,OXFORD, vol. 6, no. 21, 5 November 1996 (1996-11-05), pages 2519 - 2524, XP004135906, ISSN: 0960-894X * |
| See also references of WO9818461A1 * |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2001504456A (en) | 2001-04-03 |
| WO1998018461A1 (en) | 1998-05-07 |
| EP0946164A1 (en) | 1999-10-06 |
| AU5088498A (en) | 1998-05-22 |
| AU717283B2 (en) | 2000-03-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0934305A4 (en) | Integrin antagonists | |
| EP0946164A4 (en) | Integrin antagonists | |
| EP1007026A4 (en) | Integrin antagonists | |
| EP1047425A4 (en) | Integrin receptor antagonists | |
| AU3213799A (en) | Integrin antagonists | |
| EP0912175A4 (en) | Fibrinogen receptor antagonists | |
| EP1100506A4 (en) | Integrin receptor antagonists | |
| HU9603525D0 (en) | Vironectin receptor antagonists | |
| HU9603082D0 (en) | Neurokinine (tachykinine) antagonists | |
| EP1105389A4 (en) | Integrin receptor antagonists | |
| HK1018776A1 (en) | Muscarinic antagonists | |
| EP1007051A4 (en) | Integrin receptor antagonists | |
| EP0880511A4 (en) | Integrin receptor antagonists | |
| EP0913191A4 (en) | Microemulsion | |
| EP0885205A4 (en) | Fibrinogen receptor antagonists | |
| HU9601176D0 (en) | Adhesion-receptor antagonists | |
| EP0885213A4 (en) | Fibrinogen receptor antagonists | |
| IL134175A0 (en) | Endothelin antagonists | |
| EP1027337A4 (en) | Integrin receptor antagonists | |
| HU9503191D0 (en) | Adhesion-receptor antagonists | |
| ZA98256B (en) | Tachykinin antagonists | |
| GB9820014D0 (en) | Receptor antagonists and uses thereof | |
| ZA985209B (en) | Endothelin antagonists | |
| GB9724656D0 (en) | Local oscillator arrangement | |
| GB9616786D0 (en) | Catch |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 19990531 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE |
|
| RIC1 | Information provided on ipc code assigned before grant |
Free format text: 7C 07D 471/04 A, 7A 61K 31/435 B, 7C 07D 239/42 B, 7C 07D 213/74 B, 7C 07D 239/14 B, 7A 61K 31/44 B, 7A 61K 31/505 B |
|
| A4 | Supplementary search report drawn up and despatched |
Effective date: 20000711 |
|
| AK | Designated contracting states |
Kind code of ref document: A4 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE |
|
| 17Q | First examination report despatched |
Effective date: 20020528 |
|
| GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
| 18D | Application deemed to be withdrawn |
Effective date: 20040301 |